Abstracts tagged "Biomarkers"

Abstract Number: 0386 • ACR Convergence 2022
Quantitative Proteomic Screening Uncovers Diagnostic and Monitoring Serum Biomarkers of Ankylosing Spondylitis
Mark Hwang¹, Jessica Castillo², kamala Vanarsa², Jim Zheng³, Shervin Assassi⁴, Chandra Mohan² and John Reveille⁵, ¹McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ²University of Houston, Houston, TX, ³UTHealth School of Bioinformatics, Houston, TX, ⁴McGovern Medical School, University of Texas, Houston, TX, ⁵University of Texas McGovern Medical School, Houston, TX
Background/Purpose: We sought to discover novel serum biomarkers of ankylosing spondylitis (AS) for diagnosis and monitoring disease activity. Methods: We used biologic-treatment naïve AS and…
Abstract Number: 0616 • ACR Convergence 2022
Serum Proteomic Networks Associate with Pre-clinical Rheumatoid Arthritis Autoantibodies and Longitudinal Outcomes
Liam O'Neil¹, XIAOBO MENG¹, Caitin McFadyen¹, Marvin Fritzler² and Hani El-Gabalawy¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²University of Calgary, Calgary, AB, Canada
Background/Purpose: The detection of anti-citrullinated protein antibodies (ACPA) is associated with increased risk for development of future Rheumatoid Arthritis (RA). The biological events that underpin…
Abstract Number: 0875 • ACR Convergence 2022
Predictive Biomarkers of Tofacitinib Response and Disease Activity in Juvenile Idiopathic Arthritis Subtypes: A Longitudinal Study
Ekemini Ogbu¹, Sherry Thornton², Alyssa Sproles², Alexei Grom³, Sanjeev Dhakal⁴, Bin Huang⁵ and Hermine Brunner⁶, ¹Cincinnati Children's Hospital Medical Center, Atlanta, GA, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Cinciannati, OH, ⁶Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH
Background/Purpose: Tofacitinib has been shown to improve disease activity of several subtypes of Juvenile Idiopathic Arthritis (JIA). No known biomarkers to date predict JIA improvement…
Abstract Number: 1129 • ACR Convergence 2022
Integrated High-throughput Proteomics and Machine Learning Analysis in Systemic Lupus Erythematosus Patients Identify Distinctive Clinical Profiles and Novel Biomarkers Related to Cardiovascular Risk and Lupus Nephropathy
Chary Lopez-Pedrera¹, Tomás Cerdó², María Ángeles Aguirre-Zamorano³, Laura Muñoz-Barrera¹, Ismael Sánchez-Pareja², Pilar Font¹, María Carmen Ábalos-Aguilera⁴, Pedro Ortiz-Buitrago⁴, Nuria Barbarroja¹, Eduardo Collantes¹, Rafaela Ortega-Castro¹ and Carlos Pérez-Sánchez¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, ³Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ⁴Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is a remarkably heterogeneous autoimmune disease. At present, our knowledge of serum protein patterns related to cardiovascular (CV) risk and…
Abstract Number: 1406 • ACR Convergence 2022
Integrative Multi-omic Phenotyping in Blood Identifies Molecular Signatures and Candidate Biomarkers of ACPA-negative Rheumatoid Arthritis
Benjamin Hur¹, Kevin Cunningham², John Davis¹ and Jaeyun Sung¹, ¹Mayo Clinic, Rochester, MN, ²University of Minnesota, Rochester, MN
Background/Purpose: ACPA detection assays are often used for RA diagnosis due to their high specificity ( >90%). However, current ACPA assays (e.g., anti-CCP2 ELISA) have…
Abstract Number: 1554 • ACR Convergence 2022
Serum Biomarkers in Association with Clinical and Vascular Disease Activity in Takayasu’s Arteritis
Cameron Rankin¹, Peter Grayson², Bates Gribbons³, Kaitlin Quinn⁴, Christopher Redmond⁵ and Wanxia Tsai¹, ¹NIAMS/NIH, Bethesda, MD, ²National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³McGovern Medical School, Colleyville, TX, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ⁵National Institutes of Health, Rockville, MD
Background/Purpose: 18FDG-PET imaging can be used to directly assess vascular inflammation; however, limited access to this technology has restricted widespread adoption of this modality in…
Abstract Number: 1803 • ACR Convergence 2022
Neutrophil-to-lymphocyte Ratio Among Flaring and Non-flaring Uncontrolled Gout Patients Undergoing Pegloticase Therapy as Part of the Phase 3 Pivotal Trials
Michael Pillinger¹, Katie Obermeyer², Lissa Padnick-Silver² and Brian LaMoreaux², ¹NYU Grossman School of Medicine, New York, NY, ²Horizon Therapeutics plc, Deerfield, IL
Background/Purpose: Gout flares result from an innate immune response against monosodium urate crystal deposits, resulting in macrophage crystal phagocytosis and cellular activation.1 NLRP3 inflammasome activation…
Abstract Number: 1981 • ACR Convergence 2022
Rho-GTPase Expression Recruits CD14+ Cells to Joints in Rheumatoid Arthritis and Predicts Good Response to JAK-inhibitor Treatment
Eric Malmhäll-Bah¹, Karin Andersson², Nina Oparina², Sofia Töyrä Silfverswärd³, Malin Erlandsson² and Maria Bokarewa³, ¹Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden, ³Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
Background/Purpose: While examining arthritis development in GGTaseI-deficient mice, we found that hyperactive Rho-GTPases regulate the thymic egress of CD4+ T cells to the peripheral lymphoid…
Abstract Number: 2176 • ACR Convergence 2022
Novel Tissue Turnover Blood Markers Are Associated with Pulmonary Arterial Hypertension and NYHA Stages in Patients with Systemic Sclerosis
Signe Holm Nielsen¹, Sine Søndergaard Korsholm², Axel Diederichsen³, Morten Karsdal¹, John Bonde Knudsen⁴, Anne-Christine Bay-Jensen¹, Louise Diederichsen⁵ and Christoffer Tandrup Nielsen⁶, ¹Nordic Bioscience, Herlev, Denmark, ²Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Dept of Rheumatology, Odense University Hospital (OUH), Odense, Denmark, ³Dept of Cardiology, OUH, Odense, Denmark, Odense, ⁴Dept of Rheumatology, OUH, Odense, Denmark., Odense, ⁵Copenhagen University Hospital, Rigshospitalet, Dragør, Denmark, ⁶Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Systemic sclerosis (SSc) is characterized by vasculopathy and fibrosis of the skin and internal organs. Cardiac involvement, pulmonary arterial hypertension (PAH), and interstitial lung…
Abstract Number: 0165 • ACR Convergence 2022
Low Paraoxonase-1 Enzyme Activity in Patients with Idiopathic Inflammatory Myopathies Associates with Cancer Diagnosis
Sangmee Bae¹, Ani Shahbazian², Jennifer Wang² and Christina Charles-Schoeman³, ¹University of California Los Angeles, Los Angeles, CA, ²UCLA Medical Center, Los Angeles, CA, ³Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA
Background/Purpose: Paraoxonase 1 (PON1) is a high-density lipoprotein (HDL)- associated enzyme with antioxidative properties, which is low in activity in patients with idiopathic inflammatory myopathies…
Abstract Number: 0471 • ACR Convergence 2022
Serum Proteomics in Giant Cell Arteritis: Findings of the Giant Cell Arteritis Treatment with Ultra-short Glucocorticoids and Tocilizumab Trial (The GUSTO Trial)
Lisa Christ¹, Andrea Gloor², Florian Kollert¹, Timo Gaber³, Frank Buttgereit³, Stephan Reichenbach⁴ and Peter Villiger⁵, ¹Department of Rheumatology and Immunology, University of Bern, Inselspital, Bern, Switzerland, ²Department of Internal Medicine, University of Bern, Inselspital, Bern, Switzerland, ³Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany, ⁴University of Bern, Institute for Social and Preventive Medicine, Bern, Switzerland, ⁵Medical Center Monbijou, Rheumatology and Immunology, Bern, Switzerland
Background/Purpose: Measuring disease activity in patients with giant cell arteritis (GCA) remains challenging since appropriate biomarkers are missing, particularly, if tocilizumab (TCZ) is prescribed which…
Abstract Number: 0634 • ACR Convergence 2022
Total Interstitial Inflammation Predicts Chronic Kidney Disease Progression in Patients with Lupus Nephritis
Minh Dien Duong¹, Shudan Wang², Daniel Schwartz³, Wenzhu B. Mowrey⁴, Anna Broder⁵ and Beatrice Goilav⁶, ¹The Children's Hospital of Montefiore / Albert Einstein College of Medicine, Bronx, NY, ²Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY, ³Montefiore Medical Center / Albert Einstein College of Medicine, Bronx, NY, ⁴Albert Einstein College of Medicine, Bronx, NY, ⁵Hackensack University Medical Center, Hackensack, NJ, ⁶Children's Hospital of Montefiore / Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Kidney biopsy is a gold standard for diagnosis and prognostication of lupus nephritis (LN). While interstitial fibrosis and tubular atrophy (IFTA) predict progression to…
Abstract Number: 0883 • ACR Convergence 2022
Serum Cholesterol Loading Capacity on Macrophages Is Dependent on Oxidized Low-density Lipoprotein and Regulated by Seropositivity and C-reactive Protein in Patients with Rheumatoid Arthritis
George A Karpouzas¹, Bianca Papotti², Sarah Ormseth³, Marcella Palumbo², elizabeth Hernandez³, Maria Pia Adorni², Francesca Zimetti², Matthew Budoff⁴ and Nicoletta Ronda⁵, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²University of Parma, Parma, Italy, ³The Lundquist Institute, Torrance, CA, ⁴Harbor-UCLA Medical Center and the Lundquist Institute, Torrance, CA, ⁵University of Parma, Parma
Background/Purpose: Excessive cholesterol accumulation in macrophages underlies foam cell formation, initiation and progression of atherosclerosis. Low-density lipoprotein (LDL) oxidation and unregulated uptake by macrophages are…
Abstract Number: 1130 • ACR Convergence 2022
Identification of Novel Molecular Signatures Associated with the Therapeutic Response to DMARDs and TNFi Therapies in Rheumatoid Arthritis Patients Through High Throughput Proteomics
Carlos Pérez-Sánchez¹, Laura Muñoz-Barrera¹, Tomás Cerdó², Ismael Sánchez-Pareja², Jerusalem Calvo-Gutierrez², Rafaela Ortega-Castro¹, Montserrat Romero-Gomez², María Ángeles Aguirre-Zamorano³, María Carmen Ábalos-Aguilera⁴, Nuria Barbarroja¹, José Perez-Venegas⁵, Mª Dolores Ruiz-Montesinos⁵, Carmen Dominguez⁵, Carlos Rodriguez-Escalera⁶, Carmen Romero-Barco⁶, Antonio Fernandez-Nebro⁷, Natalia Mena Vazquez⁷, Jose Luis Marenco⁸, Julia Uceda Montañez⁸, Charo Santos⁹, Eduardo Collantes¹, Alejandro Escudero-Contreras² and Chary Lopez-Pedrera¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, ³Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ⁴Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain, ⁵Virgen Macarena University Hospital, Sevilla, Spain, ⁶Virgen de la Victoria Hospital, Málaga, Spain, ⁷Regional University Hospital of Málaga, Málaga, Spain, ⁸Virgen de Valme University Hospital, Sevilla, Spain, ⁹Virgen de Valme University Hospital, Málaga, Spain
Background/Purpose: The clinical outcome of conventional disease-modifying antirheumatic drugs (DMARDs) and TNF inhibitors (TNFi) is still unpredictable in rheumatoid arthritis (RA) patients. Thus, innovative analyses…
Abstract Number: 1415 • ACR Convergence 2022
Different Bioactive Lipid Profile Predicts Response to TNF or IL6 Inhibitors in Rheumatoid Arthritis: Result of the CorEvitas CERTAIN Comparative Effectiveness Study
Mona Alotaibi¹, Roxana Coras², Dimitrios Pappas³, Ted Mikuls⁴, Joel Kremer⁵, Geoffrey Thiele⁶, mohit jain¹ and Monica Guma⁷, ¹Department of Medicine, School of Medicine, University of California San Diego, San Diego, CA, ²University of California San Diego, San Diego, CA, ³CorEvitas, LLC, Waltham, MA, ⁴Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵The Corrona Research Foundation, Delray Beach, FL, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷UCSD, La Jolla, CA
Background/Purpose: Circulating bioactive lipids can provide information about the pathogenesis of specific diseases and potentially help predict therapeutic response. Choosing the right biological therapy earlier…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.